Watson announced that it has received approval from the FDA for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension 0.25mg/2mL and 0.5mg/2mL Unit-dose ampules, the generic equivalent to AstraZeneca‘s Pulmicort Respules.

Pulmicort Respules is a steroid used as maintenance treatment of asthma and as prophylactic therapy in children ages 12 months–8 years.

Watson plans to launch the product in 2012.

For more information call (800) 272-5525 or visit www.watson.com.